| All (n = 82) | Type 1 DM (n = 23) | Type 2 DM (n = 59) |
---|---|---|---|
Age (year) | 59.7 ± 16.2 | 46.2 ± 17.1* | 64.9 ± 12.4 |
Sex (% women) | 44 (54) | 11 (48) | 33 (56) |
Body weight (kg) | 65.5 ± 12.3 | 66.6 ± 15.1 | 65.1 ± 11.1 |
Body height (m) | 1.62 ± 0.09 | 1.65 ± 0.07* | 1.60 ± 0.09 |
BMI (kg/m2) | 25 ± 4 | 24 ± 4 | 25 ± 3 |
Duration of DM (year) | 15.3 ± 8.8 | 15.3 ± 10.3 | 15.3 ± 8.3 |
Mean glucose level (mg/dL) | 156.6 ± 36.6 | 152.2 ± 27.1 | 158.3 ± 40.1 |
Complication of DM | Â | Â | Â |
 Retinopathy (%) | 23 (28%) | 4 (17%) | 19 (32%) |
 Nephropathy (%) | 22 (27%) | 4 (17%) | 18 (31%) |
 Neuropathy (%) | 30 (37%) | 5 (22%) | 25 (42%) |
Insulin (%) | 71 (87%) | 23 (100%)* | 48 (81%) |
Sulfonylurea (%) | 8 (10%) | 0 (0%) | 8 (14%) |
Glinides (%) | 2 (2%) | 0 (0%) | 2 (3%) |
Metformin (%) | 37 (45%) | 1 (4%)* | 36 (61%) |
α-Glucosidase inhibitor (%) | 11 (13%) | 0 (0%)* | 11 (19%) |
Thiazolidinedione (%) | 4 (5%) | 0 (0%) | 4 (7%) |
DPP-4 inhibitor (%) | 23 (28%) | 0 (0%)* | 23 (39%) |
SGLT2i (%) | 6 (7%) | 0 (0%) | 6 (10%) |
GLP-1 RA (%) | 1 (1%) | 0 (0%) | 1 (2%) |
Change of treatment | Â | Â | Â |
 Increase insulin dose (%) | 40 (49%) | 14 (61%) | 26 (44%) |
 Decrease insulin dose (%) | 17 (21%) | 4 (17%) | 13 (22%) |
 Increase oral antidiabetic agent (%) | 6 (7%) | 0 (0%) | 6 (10%) |
 Decrease oral antidiabetic agent (%) | 4 (5%) | 0 (0%) | 4 (7%) |
SD (mg/dL) | 44.3 ± 16.6 | 55.1 ± 18.1* | 39.6 ± 13.6 |
MAGE (mg/dL) | 117.7 ± 34.0 | 135.4 ± 31.8* | 110.2 ± 32.3 |
CONGA-1 (mg/dL) | 29.9 ± 9.1 | 35.4 ± 8.1* | 27.6 ± 8.5 |
%CV | 28.5 ± 9.6 | 35.2 ± 10.2* | 25.6 ± 7.7 |